Chronic myelogenous leukemia

J Natl Compr Canc Netw. 2005 Nov;3(6):732-55. doi: 10.6004/jnccn.2005.0044.
No abstract available

MeSH terms

  • Algorithms
  • Antimetabolites, Antineoplastic / therapeutic use
  • Antineoplastic Agents / therapeutic use
  • Antineoplastic Agents / toxicity
  • Benzamides
  • Cell Transformation, Neoplastic
  • Chromosome Breakage
  • Chromosomes, Human, Pair 22
  • Chromosomes, Human, Pair 9
  • Cytarabine / therapeutic use
  • Cytogenetic Analysis*
  • Disease Progression
  • Drug Interactions
  • Gene Fusion
  • Hematopoietic Stem Cell Transplantation
  • Hematopoietic Stem Cells / cytology*
  • Humans
  • Imatinib Mesylate
  • Interferons / therapeutic use
  • Karyotyping
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / etiology
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
  • Piperazines / therapeutic use
  • Piperazines / toxicity
  • Practice Guidelines as Topic / standards*
  • Pyrimidines / therapeutic use
  • Pyrimidines / toxicity
  • Recombinant Fusion Proteins / chemistry
  • Recombinant Fusion Proteins / metabolism
  • Remission Induction
  • Secondary Prevention
  • Translocation, Genetic
  • Transplantation, Homologous

Substances

  • Antimetabolites, Antineoplastic
  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Recombinant Fusion Proteins
  • Cytarabine
  • Imatinib Mesylate
  • Interferons